Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CAMPATH-1H (Cambridge University).

P Rioux1

  • 1Variagenics Inc, Cambridge, MA 02139-1562, USA. prioux@csi.com

Idrugs : the Investigational Drugs Journal
|September 15, 2005
PubMed
Summary
This summary is machine-generated.

CAMPATH-1H, a T-cell-depleting antibody, shows positive preliminary results in a pivotal trial for chronic lymphocytic leukemia (CLL). Further studies are exploring its use in other conditions like vasculitis and multiple sclerosis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clues about the functional neuroanatomy of verbal working memory: a study of resting brain glucose metabolism in Parkinson's disease.

European journal of neurology·2013
Same author

Childhood cognitive ability accounts for associations between cognitive ability and brain cortical thickness in old age.

Molecular psychiatry·2013
Same author

Suicide attempts and job insecurity: a complex association.

European psychiatry : the journal of the Association of European Psychiatrists·2009
Same author

Premorbid IQ estimates from a multiple aptitude test battery: regression vs. equating.

Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists·2003
Same author

TP-10 (AVANT Immunotherapeutics).

Current opinion in investigational drugs (London, England : 2000)·2001
Same author

Use of brook char (Salvelinus fontinalis) physiological responses to stress as a teaching exercise.

Advances in physiology education·2000
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • CAMPATH-1H is a humanized monoclonal antibody targeting T-cells.
  • It is being developed for chronic lymphocytic leukemia (CLL) treatment.

Purpose of the Study:

  • To evaluate the efficacy of CAMPATH-1H in a pivotal clinical trial for CLL.
  • To explore additional therapeutic applications of CAMPATH-1H.

Main Methods:

  • A pivotal clinical trial enrolled 94 patients with CLL across 20 centers in the US and Europe.
  • Preliminary data analysis was conducted on a subset of patients.

Main Results:

  • Preliminary, unaudited results from one clinical site were positive.
  • The antibody has shown potential in reversing renal transplant rejection and in ex vivo bone marrow purging.

Related Experiment Videos

Conclusions:

  • CAMPATH-1H demonstrates promising results for CLL treatment.
  • The antibody has potential applications in autoimmune diseases, transplant medicine, and cancer therapy.